Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 9/20 | 0.43 |
| ▸ | HTR1B | P28222 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 11/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL381709 | 1.00 | ADORA2B (0.43) | ADORA2BHTR1BOPRK1FFAR4SIGMAR1 | |
| SCHEMBL3602017 | 1.00 | ADORA2B (0.43) | ADORA2BHTR1BOPRK1FFAR4SIGMAR1 | |
| SCHEMBL12020307 | 0.89 | MAPK14 (0.34) | ADORA2BHTR1BOPRK1FFAR4SIGMAR1 | |
| SCHEMBL12020287 | 0.89 | MAPK14 (0.34) | ADORA2BHTR1BOPRK1FFAR4SIGMAR1 | |
| SCHEMBL12020317 | 0.89 | MAPK14 (0.34) | ADORA2BHTR1BOPRK1FFAR4SIGMAR1 | |
| SCHEMBL1422880 | 0.88 | KDM4E (0.51) | ADORA2BHTR1BOPRK1FFAR4SIGMAR1 | |
| SCHEMBL3304369 | 0.87 | KDM4E (0.34) | ADORA2BHTR1BOPRK1FFAR4SIGMAR1 | |
| SCHEMBL10194193 | 0.84 | KDM4E (0.38) | ADORA1KDM4EALDH1A1GAAADORA2A | |
| SCHEMBL12163726 | 0.84 | KDM4E (0.38) | ADORA1KDM4EALDH1A1GAAADORA2A | |
| SCHEMBL1930482 | 0.84 | MAPT (0.53) | ADORA2BHTR1BOPRK1FFAR4SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160130230-A1 | SUBSTITUTED DICYANOPYRIDINES AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-05-12 | — | — | US | disclosed |
| US-20160130230-A1 | SUBSTITUTED DICYANOPYRIDINES AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-05-12 | — | — | US | disclosed |
| US-20160130230-A1 | SUBSTITUTED DICYANOPYRIDINES AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-05-12 | — | — | US | disclosed |
| US-9187428-B2 | Substituted dicyanopyridines and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-11-17 | — | — | US | disclosed |
| US-9187428-B2 | Substituted dicyanopyridines and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-11-17 | — | — | US | disclosed |
| US-9187428-B2 | Substituted dicyanopyridines and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-11-17 | — | — | US | disclosed |
| US-9095582-B2 | Substituted aryloxazoles and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-08-04 | — | — | US | disclosed |
| US-9095582-B2 | Substituted aryloxazoles and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-08-04 | — | — | US | disclosed |
| EP-2379540-B1 | DIPEPTOID PRODRUGS AND THE USE THEREOF | BAYER IP GMBH (DE) | 2014-10-22 | — | — | EP | disclosed |
| US-20140162981-A1 | SUBSTITUTED ARYLOXAZOLES AND THEIR USE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-06-12 | — | — | US | disclosed |
| EP-2185550-A1 | SUBSTITUTED ARYLOXAZOLES AND THE USE THEREOF | Bayer Schering Pharma AG (DE) | 2010-05-19 | — | — | EP | disclosed |
| US-20100048641-A1 | Use of Adenosine A1 and/or Dual A1/2ab Agonists for Production of Medicaments for Treating Diseases | BAYER HEALTHCARE AG LAW AND PATENTS,PATENTS AND LICENSING (DE) | 2010-02-25 | — | — | US | disclosed |
| EP-1812430-B1 | SUBSTITUTED PHENYLAMINOTHIAZOLES AND USE THEREOF | BAYER HEALTHCARE AG (DE) | 2009-04-15 | — | — | EP | disclosed |
| WO-2009015776-A1 | SUBSTITUTED ARYLOXAZOLES AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-02-05 | — | — | WO | disclosed |
| WO-2009015776-A1 | SUBSTITUTED ARYLOXAZOLES AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-02-05 | — | — | WO | disclosed |
| EP-1994031-A1 | USE OF ADENOSINE A1 AND/OR DUAL A1/A2B AGONISTS FOR PRODUCTION OF MEDICAMENTS FOR TREATING DISEASES | Bayer HealthCare AG (DE) | 2008-11-26 | — | — | EP | disclosed |
| US-20080269300-A1 | Substituted Phenylaminothiazoles and Use Thereof | BAYER HEALTHCARE AG (DE) | 2008-10-30 | — | — | US | disclosed |
| US-20080269300-A1 | Substituted Phenylaminothiazoles and Use Thereof | BAYER HEALTHCARE AG (DE) | 2008-10-30 | — | — | US | disclosed |
| WO-2007101531-A1 | USE OF ADENOSINE A1 AND/OR DUAL A1/A2B AGONISTS FOR PRODUCTION OF MEDICAMENTS FOR TREATING DISEASES | BAYER HEALTHCARE AG (DE) | 2007-09-13 | — | — | WO | disclosed |
| WO-2007101531-A1 | USE OF ADENOSINE A1 AND/OR DUAL A1/A2B AGONISTS FOR PRODUCTION OF MEDICAMENTS FOR TREATING DISEASES | BAYER HEALTHCARE AG (DE) | 2007-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048641-A1 | Use of Adenosine A1 and/or Dual A1/2ab Agonists for Production of Medicaments for Treating Diseases | ADORA1, ADORA2B, ADORA2A | ADORA2B 2/4885HTR1B 61/4885OPRK1 1821/4885 |
| US-20080269300-A1 | Substituted Phenylaminothiazoles and Use Thereof | PAH, TNNT2, VHL | ADORA2B 2425/4885HTR1B 1807/4885OPRK1 1816/4885 |
| US-20160130230-A1 | SUBSTITUTED DICYANOPYRIDINES AND USE THEREOF | QDPR, DPYD, DDC | ADORA2B 2447/4885HTR1B 3510/4885OPRK1 3006/4885 |
| US-20140162981-A1 | SUBSTITUTED ARYLOXAZOLES AND THEIR USE | CYP4X1, AHR, AGXT | ADORA2B 3238/4885HTR1B 1592/4885OPRK1 2084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.